Valneva (VLA) Partnership summary

Opening remarks and agenda

• Strategic partnership announced between Valneva and LimmaTech to accelerate development of the S4V tetravalent Shigella vaccine, with executive presentations and Q&A for analysts.

• Forward-looking statements and associated risks were highlighted, with reference to regulatory filings for further details.

• Valneva hosted a live webcast to discuss the partnership and its implications.

Objectives of the partnership

• Partnership aims to develop the first-in-class, clinically advanced tetravalent Shigella vaccine, addressing significant unmet medical need, especially in LMICs, infants, children, and travelers.

• The collaboration is expected to enhance the R&D pipeline, provide near-term upside, and align with public health and ESG objectives.

Partner introductions and roles

• Valneva receives exclusive global rights to develop, manufacture, and commercialize the S4V vaccine, leading later-stage clinical development and commercialization.

• LimmaTech brings expertise in vaccine technology and bioconjugation, conducting initial Phase 2 trials and transferring technology and IND to Valneva after Phase 2 enrollment.